TABLE 7.
Percent of Pathogens Reported From Catheter-Associated Urinary Tract Infections (CAUTIs) That Tested Resistant to Selected Antimicrobial Agents, by Period, 2011–2014
| Pathogen, antimicrobial | 2011 | 2012 | 2013 | 2014 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of isolates reported | % of isolates testeda | % Resistance | No. of isolates reported | % of isolates testeda | % Resistance | No. of isolates reported | % of isolates testeda | % Resistance | No. of isolates reported | % of isolates testeda | % Resistance | |
| Staphylococcus aureus | 328 | 665 | 742 | 780 | ||||||||
| OX/METH/CEFOX | 96.6 | 55.8 | 92.9 | 56.8 | 92.7 | 55.5 | 92.9 | 52.0 | ||||
| Enterococcus spp. | ||||||||||||
| E. faecium | 598 | 1,148 | 1,255 | 1,211 | ||||||||
| VAN | 96.2 | 83.8 | 96.6 | 86.0 | 96.5 | 86.2 | 96.1 | 85.1 | ||||
| E. faecalis | 1,460 | 2,911 | 3,112 | 3,245 | ||||||||
| VAN | 94.1 | 7.1 | 92.2 | 7.4 | 92.5 | 9.1 | 93.6 | 8.0 | ||||
| Klebsiella (pneumoniae/oxytoca) | 2,035 | 4,170 | 4,541 | 4,725 | ||||||||
| ESC4 | 84.2 | 21.8 | 84.6 | 20.6 | 85.3 | 23.9 | 84.6 | 22.5 | ||||
| Carbapenems | 67.3 | 10.7 | 71.8 | 9.1 | 71.1 | 10.9 | 68.8 | 9.5 | ||||
| MDR1 | 90.3 | 14.8 | 91.2 | 15.0 | 93.5 | 17.2 | 93.2 | 14.6 | ||||
| Escherichia coli | 4,826 | 10,512 | 10,628 | 10,840 | ||||||||
| ESC4 | 82.8 | 12.9 | 82.6 | 12.8 | 84.0 | 15.5 | 84.0 | 16.1 | ||||
| FQ3 | 96.3 | 32.7 | 96.1 | 31.0 | 96.2 | 35.4 | 96.3 | 34.8 | ||||
| Carbapenems | 63.8 | 1.2 | 66.2 | 0.8 | 67.5 | 1.0 | 66.6 | 1.1 | ||||
| MDR1 | 87.8 | 5.5 | 89.4 | 6.2 | 92.8 | 8.1 | 93.7 | 8.0 | ||||
| Enterobacter spp. | 727 | 1,614 | 1,707 | 1,641 | ||||||||
| ESC4 | 93.1 | 40.6 | 92.7 | 39.5 | 91.9 | 38.8 | 92.9 | 40.5 | ||||
| Carbapenems | 67.1 | 3.9 | 68.7 | 4.2 | 67.9 | 7.1 | 70.7 | 6.5 | ||||
| MDR1 | 92.0 | 10.5 | 95.2 | 9.4 | 94.8 | 10.5 | 95.2 | 11.2 | ||||
| Pseudomonas aeruginosa | 2,023 | 4,320 | 4,848 | 4,657 | ||||||||
| AMINOS | 94.4 | 25.1 | 97.8 | 19.9 | 97.6 | 22.4 | 97.6 | 21.1 | ||||
| ESC2 | 95.9 | 25.0 | 96.0 | 22.3 | 95.6 | 24.0 | 96.3 | 22.5 | ||||
| FQ2 | 96.6 | 34.5 | 96.7 | 31.2 | 96.4 | 34.0 | 96.7 | 32.6 | ||||
| Carbapenems | 78.6 | 22.3 | 80.8 | 20.9 | 82.1 | 24.8 | 80.6 | 23.9 | ||||
| PIP/PIPTAZ | 77.4 | 16.5 | 77.2 | 15.1 | 86.8 | 15.8 | 89.5 | 15.5 | ||||
| MDR2 | 97.2 | 18.6 | 97.9 | 16.7 | 97.5 | 19.3 | 97.6 | 17.7 | ||||
| Acinetobacter spp. | 158 | 294 | 345 | 276 | ||||||||
| Carbapenems | 73.4 | 69.0 | 75.5 | 57.7 | 78.8 | 66.5 | 81.5 | 64.0 | ||||
| MDR3 | 98.7 | 75.6 | 96.9 | 64.6 | 96.8 | 73.1 | 96.0 | 69.1 | ||||
NOTE. OX/METH/CEFOX, oxacillin/methicillin/cefoxitin; VAN, vancomycin; ESC4, extended-spectrum cephalosporin (cefepime, cefotaxime, ceftazidime, ceftriaxone); Carbapenems (imipenem, meropenem, doripenem); MDR1, multidrug-resistance (must test either intermediate [I] or resistant [R] to at least 1 drug in 3 of the 5 following classes [ESC4, FQ3, AMINO, carbapenems, & PIP/PIPTAZ]); FQ3, fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin); AMINOS, aminoglycosides (amikacin, gentamicin, tobramycin); ESC2, extended-spectrum cephalosporin (cefepime, ceftazidime); FQ2, fluoroquinolones (ciprofloxacin, levofloxacin); PIP, piperacillin; PIPTAZ, piperacillin/tazobactam; MDR2, multidrug-resistance (must test either I or R to at least 1 drug in 3 of the 5 following classes [ESC2, FQ2, AMINOS, carbapenems, & PIP/PIPTAZ]); MDR3, multidrug-resistance (must test either I or R to at least 1 drug in 3 of the 6 following classes [ESC4, FQ2, AMINOS, carbapenems, PIP/PIPTAZ, & ampicillin/sulbactam]).
f the percent of isolates tested is less than 70%, caution should be used when interpreting the percent resistance.